Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

RASILEZ DIN 02302071

Status: Cancelled Post Market
Holder: NODEN PHARMA DAC
Molecule: ALISKIREN (ALISKIREN FUMARATE)
Available to quote

Health Canada record

Active ingredient(s)ALISKIREN (ALISKIREN FUMARATE) 300 MG
Dosage formTablet
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCC09XA02 ALISKIREN
Original market date29-Nov-2007
Current status date31-Aug-2023
SourceHealth Canada DPD

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing ALISKIREN (ALISKIREN FUMARATE)

DINProductCompanyFormStrengthStatus
02302063RASILEZNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 150 MGCancelled Post Market
02332728RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 150 MG; HYDROCHLOROTHIAZIDE 12.5 MGCancelled Post Market
02332736RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 150 MG; HYDROCHLOROTHIAZIDE 25 MGCancelled Post Market
02332744RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 300 MG; HYDROCHLOROTHIAZIDE 12.5 MGCancelled Post Market
02332752RASILEZ HCTNODEN PHARMA DACTabletALISKIREN (ALISKIREN FUMARATE) 300 MG; HYDROCHLOROTHIAZIDE 25 MGCancelled Post Market
02441896SANDOZ ALISKIRENSANDOZ CANADA INCORPORATEDTabletALISKIREN (ALISKIREN FUMARATE) 150 MGCancelled Pre Market
02441918SANDOZ ALISKIRENSANDOZ CANADA INCORPORATEDTabletALISKIREN (ALISKIREN FUMARATE) 300 MGCancelled Pre Market

Notices of Compliance

NOCDateSubmissionReason
203042018-01-12New Drug Submission (NDS)MERGER - BUYOUT
91702007-11-14New Drug Submission (NDS)
Request a quote for RASILEZ

How to read a Canadian DIN record